In a strategic move within the hematology field, French pharmaceutical company MITEM Pharma has successfully acquired the global rights to Desferal (deferoxamine) from Novartis. Desferal, an essential medicine listed by the World Health Organization (WHO), is a vital injectable treatment widely utilized for managing iron overload conditions resulting from blood transfusions in patients with beta-thalassemia and sickle cell anemia. Supported by TechLife Capital, Groupe Macsf, and additional investments from Access Capital Partners and SWEN Capital Partners, this acquisition not only underscores Mitem Pharma’s growth strategy but also reinforces its international expansion and dedication to ensuring the most effective solutions for rare blood disorders.
At OxyDial, we believe this acquisition marks a significant advancement in the treatment of beta-thalassemia and sickle cell anemia. This development highlights the continuous progress in hematology research and underscores the importance of sustained clinical efforts in enhancing patient care for rare diseases.
Read more: https://lnkd.in/eU68ibaD
#MitemPharma #Desferal #Hematology #IronOverload #BetaThalassaemia #SickleCellAnemia #ClinicalResearch #RareDiseases #MedicalAdvancements